Brotchie J - Search Results

1

Dihydropyridine calcium channel blockers and the progression of parkinsonism.

Marras C, Gruneir A, Rochon P, Wang X, Anderson G, Brotchie J, Bell CM, Fox S, Austin PC. Marras C, et al. Among authors: brotchie j. Ann Neurol. 2012 Mar;71(3):362-9. doi: 10.1002/ana.22616. Ann Neurol. 2012. PMID: 22451203

2

Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat.

Fox S, Brotchie J. Fox S, et al. Among authors: brotchie j. Eur J Pharmacol. 1996 Apr 22;301(1-3):27-30. doi: 10.1016/0014-2999(96)00100-8. Eur J Pharmacol. 1996. PMID: 8773443

3

New treatments for movement disorders?

Fox SH, Brotchie JM. Fox SH, et al. Among authors: brotchie jm. Trends Pharmacol Sci. 1996 Oct;17(10):339-42. doi: 10.1016/s0165-6147(96)30018-7. Trends Pharmacol Sci. 1996. PMID: 8979766 No abstract available.

4

Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Fox SH, Moser B, Brotchie JM. Fox SH, et al. Among authors: brotchie jm. Exp Neurol. 1998 May;151(1):35-49. doi: 10.1006/exnr.1998.6792. Exp Neurol. 1998. PMID: 9582253

5

Quantitative assessment of dyskinesias in subhuman primates.

Brotchie JM, Fox SH. Brotchie JM, et al. Mov Disord. 1999;14 Suppl 1:40-7. Mov Disord. 1999. PMID: 10493402 Review. No abstract available.

6

5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.

Fox SH, Brotchie JM. Fox SH, et al. Among authors: brotchie jm. Eur J Pharmacol. 2000 Jun 9;398(1):59-64. doi: 10.1016/s0014-2999(00)00238-7. Eur J Pharmacol. 2000. PMID: 10856448

7

5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease.

Fox SH, Brotchie JM. Fox SH, et al. Among authors: brotchie jm. Mov Disord. 2000 Nov;15(6):1064-9. doi: 10.1002/1531-8257(200011)15:6<1064::aid-mds1002>3.0.co;2-c. Mov Disord. 2000. PMID: 11104187

8

Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Henry B, Fox SH, Crossman AR, Brotchie JM. Henry B, et al. Among authors: brotchie jm. Exp Neurol. 2001 Sep;171(1):139-46. doi: 10.1006/exnr.2001.7727. Exp Neurol. 2001. PMID: 11520128

9

Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.

Hille CJ, Fox SH, Maneuf YP, Crossman AR, Brotchie JM. Hille CJ, et al. Among authors: brotchie jm. Exp Neurol. 2001 Nov;172(1):189-98. doi: 10.1006/exnr.2001.7763. Exp Neurol. 2001. PMID: 11681851

10

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.

Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Sieradzan KA, et al. Among authors: brotchie jm. Neurology. 2001 Dec 11;57(11):2108-11. doi: 10.1212/wnl.57.11.2108. Neurology. 2001. PMID: 11739835 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

226 results

Search Page

Filters